Treating Resistant High Blood Pressure: New Drugs and Devices on the Horizon | Research

The takeaway

A review examines emerging therapies for resistant hypertension including RNA-based agents, aldosterone synthase inhibitors, and device-based interventions alongside GLP-1 RAs.

BP ≥130/80 despite 3+ drugs
Resistant hypertension requires novel therapeutic approaches beyond conventional medications

What the researchers found

Multiple novel therapeutic approaches for resistant hypertension are advancing, including RNA-based therapies, new mineralocorticoid antagonists, and device-based interventions.

Why it matters

Resistant hypertension affects millions and significantly increases cardiovascular risk. New therapeutic options are desperately needed for patients who don't respond to existing drugs.

How the study worked

Narrative review of emerging pharmacological and interventional therapies for resistant hypertension.

What this study cannot tell us

Review of emerging therapies — many are in clinical trials without definitive outcome data; practical integration into clinical care not yet established.

How to read the evidence

Narrative review — provides a comprehensive overview of the emerging therapeutic landscape but most agents lack definitive outcome trial data.

When this study was published

Published 2026 in Reviews in Cardiovascular Medicine.

The bigger picture

The convergence of RNA therapeutics, improved neurohormonal targeting, and device-based interventions is creating a new era in hypertension management for the hardest-to-treat patients.

Questions still open

Which emerging therapy will most impact resistant hypertension management?
Can combination of novel agents replace the need for renal denervation?

Common questions

What is resistant hypertension?

It's high blood pressure that remains uncontrolled despite taking three or more blood pressure medications at maximum doses, including a diuretic. It affects about 10-15% of hypertension patients.

Can GLP-1 drugs help with high blood pressure?

Yes — GLP-1 RAs have blood pressure-lowering effects, particularly in patients with obesity, making them a useful addition for resistant hypertension with metabolic comorbidities.

Read the original research

Resistant Hypertension: Integration of Novel Agents and Interventional Approaches in Clinical Practice.

Reviews in cardiovascular medicine, 27(1), 45429

View on PubMed ↗Publisher’s paper ↗

Citation

Arriola-Montenegro, Jose; Chaponan-Lavalle, Andres; Nombera-Aznaran, Natalia; Abdalla, Mohammed; Bizer, Benjamin; Mohan, Arjunmohan; Muñoz Verdugo, Irma Andrea; Zardoost, Pooya; Ordaya-Gonzales, Karina; Villarreal Rizzo, Alan; Rios-Garcia, Wagner; Yip, Laverne Kar Yin; Gonzalez Suarez, Maria L. (2026). Resistant Hypertension: Integration of Novel Agents and Interventional Approaches in Clinical Practice.. Reviews in cardiovascular medicine, 27(1), 45429. https://doi.org/10.31083/RCM45429